急诊经导管主动脉瓣置换术疗效的多中心初步评估
该回顾性多中心研究纳入8家中心48例急诊TAVR患者,评估其有效性与安全性。器械置入成功率91.7%,术后跨瓣压差、左心室射血分数及NT-proBNP均显著改善;院内全因死亡率8.3%,30天、1年及2年生存率分别为91.7%、89.6%、89.6%。结论提示急诊TAVR对失代偿性主动脉瓣重度狭窄可能安全有效。
要点
- 急诊TAVR器械置入成功率91.7%,术后血流动力学及心功能指标显著改善。
- 院内全因死亡率8.3%,主要血管并发症10.4%,急性肾损伤12.5%。
- 术后30天、1年及2年生存率分别为91.7%、89.6%、89.6%。
核心结论
- 对于急危重症状态的失代偿性主动脉瓣重度狭窄患者,急诊TAVR可能是一种安全有效的治疗手段。
研究设计与样本
- 回顾性多中心研究,纳入2017年5月至2020年12月8家中心行急诊TAVR的48例患者。
- 收集机械循环辅助装置使用情况及手术前后NT-proBNP和超声心动图结果。
- 主要终点为全因死亡,次要终点包括卒中、大出血、主要血管并发症、心肌梗死、永久起搏器置入和急性肾损伤。
- 采用Kaplan-Meier生存曲线估计随访期间生存率。
主要发现
- 器械置入成功率为91.7%(44/48)。
- 术后平均主动脉瓣跨瓣压差较术前降低[(12.3±6.4)mmHg比(60.2±23.8)mmHg,P<0.000 1]。
- 左心室射血分数升高[(41.5±11.7)%比(31.0±11.3)%,P<0.000 1]。
- NT-proBNP下降[3 492.0(1 638.8,7 165.5)ng/L比12 418.5(6 693.8,35 000.0)ng/L,P<0.000 1]。
- 院内全因死亡率为8.3%(4/48),卒中2.1%(1/48),大出血6.3%(3/48),主要血管并发症10.4%(5/48),心肌梗死4.2%(2/48),永久起搏器置入6.3%(3/48),急性肾损伤12.5%(6/48)。
关键数值与推荐
- 器械置入成功指患者存活,单个人工主动脉瓣置入位置合适且术后平均主动脉瓣跨瓣压差<20 mmHg或主动脉瓣峰值流速<3 m/s,同时无中度及以上人工主动脉瓣膜反流。
临床怎么用
- 对于急危重症状态的失代偿性主动脉瓣重度狭窄患者,急诊TAVR可作为考虑的治疗选择。
- 急诊TAVR围术期需关注主要血管并发症和急性肾损伤,并合理使用机械循环辅助装置。
局限性
- 本研究为回顾性研究,样本量较小(48例),随访时间有限(中位196 d)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objectives: To explore the efficacy and safety of emergency transcatheter aortic valve replacement (TAVR). Methods: Data of patients who underwent emergency TAVR in eight centers, namely Fuwai Hospital, Wuhan Asia Heart Hospital, Xijing Hospital, Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Guangdong Provincial People's Hospital, Zhongshan Hospital Affiliated to Fudan University, the First Affiliated Hospital of Zhengzhou University, the Second Xiangya Hospital of Central South University, between May 2017 and December 2020 were retrospectively analyzed. The use of mechanical circulatory support system (MCS) and the results of laboratory tests (N-terminal B-type natriuretic peptide (NT-proBNP)) and echocardiography (mean aortic valve cross valve pressure difference and left ventricular ejection fraction) before and after operation were collected. The primary endpoint was all-cause death, and the secondary endpoints were stroke, major bleeding, major vascular complications, myocardial infarction, permanent pacemaker implantation, and acute renal injury. Device success was caculated, which refered to absence of procedural mortality and correct positioning of a single prosthetic heart valve into the proper anatomical location and intended performance of the prosthetic heart valve (mean aortic valve gradient<20 mmHg(1 mmHg=0.133 kPa) or peak velocity<3 m/s, with no moderate or severe prosthetic valve regurgitation). Kaplan-Meier survival curve was used to estimate the survival rate of patients during follow-up. Results: This study included 48 patients. The age was (72.5±8.1) years, and 34 patients were males (70.8%). Device success rate was 91.7% (44/48). The mean aortic valve transvalvular pressure was significantly decreased after operation ((12.3±6.4)mmHg vs. (60.2±23.8)mmHg, P<0.000 1). Left ventricular ejection fraction was significantly increased ((41.5±11.7)% vs. (31.0±11.3)%, P<0.000 1). NT-proBNP significantly decreased (3 492.0 (1 638.8, 7 165.5) ng/L vs. 12 418.5 (6 693.8, 35 000.0) ng/L, P<0.000 1). In-hospital all-cause mortality was 8.3% (4/48). During hospitalization, the rate of stroke was 2.1% (1/48), major bleeding was 6.3% (3/48), major vascular complications was 10.4% (5/48), myocardial infarction was 4.2% (2/48), permanent pacemaker implantation was 6.3% (3/48), and the rate of acute renal injury was 12.5% (6/48). MCS was used in 20 patients (41.7%). The median follow-up time was 196 days. During the follow-up, one patient died (due to systemic metastasis of pancreatic cancer), two cases suffered new myocardial infarction and one case received permanent pacemaker implantation. The survival rate of 30 days, 1 year and 2 years after the operation were 91.7% (44/48), 89.6% (43/48), 89.6% (43/48), respectively. Conclusion: Emergency TAVR may be a safe and effective treatment for patients with severe decompensated aortic valve stenosis. 目的: 初步探讨急诊经导管主动脉瓣置换术(TAVR)的有效性及安全性。 方法: 该研究为回顾性研究。入选2017年5月至2020年12月于中国医学科学院阜外医院、广东省人民医院、华中科技大学同济医学院附属协和医院、第四军医大学西京医院、上海复旦大学附属中山医院、武汉亚洲心脏病医院、郑州大学第一附属医院、中南大学湘雅二医院8家中心行急诊TAVR的患者。收集机械循环辅助装置(MCS)使用情况及手术前后实验室检验[N末端B型利钠肽原(NT-proBNP)]及超声心动图检查结果(平均主动脉瓣跨瓣压差、左心室射血分数)。主要终点事件为全因死亡,次要终点事件为卒中、大出血、主要血管并发症、心肌梗死、永久起搏器置入、急性肾损伤。计算器械置入成功率,器械置入成功指患者存活,单个人工主动脉瓣置入位置合适且术后平均主动脉瓣跨瓣压差<20 mmHg(1 mmHg=0.133 kPa)或主动脉瓣峰值流速<3 m/s,同时无中度及以上人工主动脉瓣膜反流。采用Kaplan-Meier生存曲线法估计患者随访期间生存率。 结果: 共纳入48例患者,年龄(72.5±8.1)岁,其中男性34例(70.8%)。器械置入成功率为91.7%(44/48)。全部患者的术后平均主动脉瓣跨瓣压差较术前降低[(12.3±6.4)mmHg比(60.2±23.8)mmHg,P<0.000 1],左心室射血分数升高[(41.5±11.7)%比(31.0±11.3)%,P<0.000 1],NT-proBNP下降[3 492.0(1 638.8,7 165.5)ng/L比12 418.5(6 693.8,35 000.0)ng/L,P<0.000 1]。入选患者的院内全因死亡率为8.3%(4/48),住院期间卒中发生率为2.1%(1/48),大出血发生率为6.3%(3/48),主要血管并发症发生率为10.4%(5/48),心肌梗死发生率为4.2%(2/48),永久起搏器置入率为6.3%(3/48),急性肾损伤发生率为12.5%(6/48)。20例患者应用了MCS,使用率达41.7%。中位随访时间196 d,随访期间全因死亡1例(因胰腺癌全身转移),新增心肌梗死2例,置入永久起搏器1例。术后30 d、1年及2年的生存率分别为91.7%(44/48)、89.6%(43/48)、89.6%(43/48)。 结论: 对于急危重症状态的失代偿性主动脉瓣重度狭窄患者,急诊TAVR可能是一种安全有效的治疗手段。.
引用
- Zhou Z, Zhang LY, Yang J, et al. [Preliminary evaluation on the efficacy of emergency transcatheter aortic valve replacement: a multicenter study]. Zhonghua Xin Xue Guan Bing Za Zhi. 2022. PMID: 35856227. doi:10.3760/cma.j.cn112148-20220601-00434
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。